Literature DB >> 11166144

Cathepsin D expression as a possible predictor of lymph node metastasis in submucosal colorectal cancer.

H Oh-e1, S Tanaka, Y Kitadai, F Shimamoto, M Yoshihara, K Haruma.   

Abstract

The aim of this study was to clarify the usefulness of cathepsin D expression as a predictor of lymph node metastasis in submucosal colorectal cancer (CRC). Cathepsin D expression was examined immunohistochemically in cancer and stromal cells located at the deepest portion of 254 invasive tumours that had been resected from patients with submucosal CRC. In cancer cells, the expression was classified according to differences in intracellular localisation: polarity positive, apical type (PA); polarity positive, basal type (PB); polarity negative (PN); or no expression (NE). Lesions with PN or NE expression showed a significantly higher incidence of lymph node metastasis than those with PA or PB expression. Alternatively, lesions with positive expression in stromal cells showed a significantly higher incidence of lymph node metastasis than that of those with negative expression. None of the lesions with PA or PB expression and negative expression in stromal cells had metastasised to the lymph node. In conclusion, analysis combining cathepsin D expression in cancer and stromal cells may be a quite useful predictor for lymph node metastasis and may broaden the indications for curative endoscopic treatment of submucosal CRC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166144     DOI: 10.1016/s0959-8049(00)00348-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Clinical significance of type V(I) pit pattern subclassification in determining the depth of invasion of colorectal neoplasms.

Authors:  Hiroyuki Kanao; Shinji Tanaka; Shiro Oka; Iwao Kaneko; Shigeto Yoshida; Koji Arihiro; Masaharu Yoshihara; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

Review 2.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

Review 3.  Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases.

Authors:  Sean C Glasgow; Joshua I S Bleier; Lawrence J Burgart; Charles O Finne; Ann C Lowry
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

4.  Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer.

Authors:  Iwao Kaneko; Shinji Tanaka; Shiro Oka; Shigeto Yoshida; Toru Hiyama; Koji Arihiro; Fumio Shimamoto; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

5.  A novel aspartate protease gene, ALP56, is related to morphological features of colorectal adenomas.

Authors:  Naoki Tsuji; Kei Kondoh; Momoko Furuya; Daisuke Kobayashi; Atsuhito Yagihashi; Yoshiyuki Inoue; Takashi Meguro; Shoichi Horita; Hiroshi Takahashi; Naoki Watanabe
Journal:  Int J Colorectal Dis       Date:  2003-06-11       Impact factor: 2.571

Review 6.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays.

Authors:  Chandra Kirana; Hongjun Shi; Emma Laing; Kylie Hood; Rose Miller; Peter Bethwaite; John Keating; T William Jordan; Mark Hayes; Richard Stubbs
Journal:  Int J Proteomics       Date:  2012-08-07

8.  Increased expression of cathepsin D is required for L1-mediated colon cancer progression.

Authors:  Sayon Basu; Sanith Cheriyamundath; Nancy Gavert; Thomas Brabletz; Gal Haase; Avri Ben-Ze'ev
Journal:  Oncotarget       Date:  2019-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.